Filament’s industry-leading IP portfolio now consists of ten patents for methods of extracting and standardizing natural psychedelic compounds VANCOUVER, BC, Nov. 30, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced that it has been issued two new patents for the…
